GLPwatch
Papers (10376)
Page 74 of 173, ranked by citation count.
- Lixisenatide, a Once-Daily Prandial Glucagon-Like Peptide-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes.
- Liraglutide, a GLP-1 Receptor Agonist, Which Decreases Hypothalamic 5-HT2A Receptor Expression, Reduces Appetite and Body Weight Independently of Serotonin Synthesis in Mice.
- Exenatide preserves trabecular bone microarchitecture in experimental ovariectomized rat model.
- Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: a case report.
- Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis.
- Liraglutide pharmacokinetics and dose-exposure response in Asian subjects with Type 2 diabetes from China, India and South Korea.
- Exenatide induces autophagy and prevents the cell regrowth in HepG2 cells.
- Semaglutide Ameliorates Hepatocyte Steatosis in a Cell Co-Culture System by Downregulating the IRE1α-XBP1-C/EBPα Signaling Pathway in Macrophages.
- How 'miracle' weight-loss semaglutide promises to change medicine but can we afford the expense?
- Liraglutide Accelerates Ischemia-Induced Angiogenesis in a Murine Diabetic Model.
- Protective Effects of Liraglutide and Linagliptin in C. elegans as a New Model for Glucose-Induced Neurodegeneration.
- Pharmacodynamical effects of orally administered exenatide nanoparticles embedded in gastro-resistant microparticles.
- Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2).
- Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential.
- The influence of age and metformin treatment status on reported gastrointestinal side effects with liraglutide treatment in type 2 diabetes.
- Magnetically-driven implantable pump for on-demand bolus infusion of short-acting glucagon-like peptide-1 receptor agonist.
- Acute effects of glucagon-like peptide-1, GLP-1<sub>9-36 amide</sub>, and exenatide on mesenteric blood flow, cardiovascular parameters, and biomarkers in healthy volunteers.
- Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction-associated steatotic liver disease: Post hoc analysis of three randomised controlled trials.
- Nonclinical safety and pharmacokinetics of Miglyol 812: A medium chain triglyceride in exenatide once weekly suspension.
- GLP-1 and the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential.
- Systemic Allergic Reaction to the GLP-1 Receptor Agonist Exenatide.
- Improved Localization of Insulinomas Using <sup>68</sup>Ga-NODAGA-Exendin-4 PET/CT.
- Glucagon-related peptides from phylogenetically ancient fish reveal new approaches to the development of dual GCGR and GLP1R agonists for type 2 diabetes therapy.
- Liraglutide treatment for the prevention of glucose tolerance deterioration in women with prior gestational diabetes mellitus: A 52-week randomized controlled clinical trial.
- Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system.
- Glucagon-like Peptide-1 Agonists: What the Orthopaedic Surgeon Needs to Know.
- Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials.
- GLP-1 preserves β cell function via improvement on islet insulin signaling in high fat diet feeding mice.
- In vitro metabolic stability of exendin-4: pharmacokinetics and identification of cleavage products.
- A real-world disproportionality analysis of semaglutide: Post-marketing pharmacovigilance data.
- Why are we still in need for novel anti-obesity medications?
- Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE.
- Semaglutide outperforms insulin in restoring neutrophil function against implant-related infection in diabetic and obese mice: experimental research.
- Effect of the glucagon-like peptide-1 receptor agonist lixisenatide on postprandial hepatic glucose metabolism in the conscious dog.
- Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
- Comparing the effectiveness of long-term use of daily and weekly glucagon-like peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: a network meta-analysis.
- Effect of GLP-1RA Treatment on Adhesion Molecules and Monocyte Chemoattractant Protein-1 in Diabetic Patients with Atherosclerosis.
- Effect of bariatric surgery combined with medical therapy versus intensive medical therapy or calorie restriction and weight loss on glycemic control in Zucker diabetic fatty rats.
- Exenatide-loaded inside-porous poly(lactic-co-glycolic acid) microspheres as a long-acting drug delivery system with improved release characteristics.
- Chronic exendin-4 treatment prevents the development of cancer cachexia symptoms in male rats bearing the Yoshida sarcoma.
- Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats.
- Liraglutide in oral antidiabetic drug combination therapy.
- Exendin‑4 promotes osteogenic differentiation of adipose‑derived stem cells and facilitates bone repair.
- Peptide ligations accelerated by N-terminal aspartate and glutamate residues.
- Liraglutide Improves PCOS Symptoms in Rats by Targeting FDX1.
- Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials.
- Novel double-layered PLGA microparticles-dissolving microneedle (MPs-DMN) system for peptide drugs sustained release by transdermal delivery.
- Establishment of a method for in-vivo SPECT/CT imaging analysis of <sup>111</sup>In-labeled exendin-4 pancreatic uptake in mice without the need for nephrectomy or a secondary probe.
- A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the Treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health.
- Microvascular Density and Circulating Endothelial Progenitor Cells Before and After Treatment with Incretin Mimetics in Diabetic Patients.
- Liraglutide and the management of overweight and obesity in people with severe mental illness: qualitative sub-study.
- Obestatin can potentially differentiate Wharton's jelly mesenchymal stem cells into insulin-producing cells.
- Ecological momentary assessment and cue-elicited drug craving as primary endpoints: study protocol for a randomized, double-blind, placebo-controlled clinical trial testing the efficacy of a GLP-1 receptor agonist in opioid use disorder.
- Heterologous Expression and Delivery of Biologically Active Exendin-4 by Lactobacillus paracasei L14.
- Functional association of the N-terminal residues with the central region in glucagon-related peptides.
- Optimization of Enzymolysis Clearance Strategy To Enhance Renal Clearance of Radioligands.
- Effect of exenatide on peripheral nerve excitability in type 2 diabetes.
- Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.
- Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain.
- Effectiveness of tirzepatide in patients with HFpEF using a target trial emulation retrospective cohort study.